Retrospective Evaluation of CML Patients in the National Compassionate Program
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This observational study aims at assessing the tolerability and safety profiles of Ponatinib,
a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is
used during the chronic phase of the disease, according to the Italian national compassionate
law 648/96.